Medical Communications
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
April 23, 2024 Medical Communications Anktiva, FDA, ImmunityBio, Oncology, bladder cancer
EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment
April 22, 2024 Medical Communications Emblaveo, European Commission, Immunology, Pfizer
Roche’s Alecensa approved by FDA as lung cancer treatment
April 19, 2024 Medical Communications FDA, Oncology, Roche, lung cancer
GSK’s meningococcal vaccine candidate accepted for FDA review
April 16, 2024 Medical Communications FDA, GSK, Immunology, meningococcal
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
April 15, 2024 Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer
Baxter expands US portfolio with new injectables
April 12, 2024 Medical Communications Pharmacy, baxter, injectables, product launch
NICE recommends migraine treatment for NHS use
April 11, 2024 Medical Communications NHS, NICE, Neurology, migraine
Gilead’s Veklury recommended by NICE for COVID-19 treatment
April 9, 2024 Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir
FDA accepts UCB’s sBLA for Bimzelx
April 5, 2024 Medical Communications Bimzelx, FDA, Pharmacy, UCB, sBLA
FDA approves Basilea’s antibiotic Zevtera for three indications
April 4, 2024 Medical Communications Basilea Pharmaceutica, FDA, Infections and infestations, Zevtera, antibiotic
FDA approves Eko Health’s AI for heart failure detection
April 3, 2024 Medical Communications Cardiology, Eko Health, FDA, heart failure, low ejection fraction
FDA approves Merck’s Winrevair for PAH treatment
March 27, 2024 Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
March 25, 2024 Medical Communications AstraZeneca, FDA, Neurology, Ultomiris, neuromyelitis optica spectrum disorder
FDA approves J&J’s Opsynvi for PAH treatment
March 25, 2024 Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension
FDA approves Idorsia’s Tryvio for treatment of high blood pressure
March 22, 2024 Medical Communications Cardiology, FDA, Tryvio, blood pressure, blood presure, hypertension
Latest content
